01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc., Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Propagermanium and irbesartan: Interim Phase II data

Interim data from 11 CKD patients with proteinuria who completed the 90 mg dose level in the dose-escalation part A of an open-label, Australian Phase II trial showed DMX-200 led to about a >=50% reduction...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Sparsentan: Phase II data

Top-line combined data from the 3 sparsentan cohorts in the double-blind, international Phase II DUET trial in 96 evaluable patients with focal segmental glomerulosclerosis showed that once-daily oral sparsentan met the primary endpoint of reducing...
07:00 , Sep 7, 2016 |  BC Extra  |  Clinical News

Retrophin jumps on Phase II FSGS data

Retrophin Inc. (NASDAQ:RTRX) rose $4.49 (28%) to $20.81 on Wednesday after it said combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021) met the trial's primary endpoint to...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Sparsentan: Completed Phase II enrollment

Retrophin completed enrollment of >100 patients in the double-blind, international Phase II DUET trial comparing 200, 400 and 800 mg oral RE-021 once daily for 8 weeks vs. once-daily oral irbesartan. Patients are eligible to...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Propagermanium and irbesartan: Phase II started

Sun began an open-label, Australian Phase II trial of thrice-daily oral propagermanium in up to 60 patients receiving stable irbesartan. The first part of the trial will enroll up to 30 patients and evaluate escalating...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Shionogi sales and marketing update

Shionogi launched once-daily, oral Irtra irbesartan/trichloromethiazide in Japan to treat hypertension. The low dose tablet contains 100 mg irbesartan and 1 mg trichloromethiazide and the high dose tablet contains 200 mg irbesartan and 1...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Irtra irbesartan/trichloromethiazide regulatory update

Shionogi said Japan approved Irtra irbesartan/trichloromethiazide to treat hypertension. The pharma said it plans to launch Irtra "soon" after National Health Insurance (NHI) listing. The product is a combination of irbesartan, an angiotensin II...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Aprovel irbesartan regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2)...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

CoAprovel irbesartan/hydrochlorothiazide regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2)...